Text Box: NukeMed, Inc. was founded in 2004 with the intention of designing robotic and  tungsten products for Nuclear Medicine applications, with the main focus being safety and shielding.  Our products include Hot Cells, Laminar Flow Hoods, Syringe Shields and Shipping Containers.  NukeMed, Inc. has designed an automated dose compounding machine, The Nuclear Pharm-Assist™, to reduce exposure, dispensing errors and biological contaminants.  We designed our machine without the use of lead products.  Lead is a soft and hazardous neurotoxin which can be easily transferred  to the technician handling the doses or to the patient who is being injected with or ingesting a radiopharmaceutical.  NukeMed, Inc. utilizes Tungsten for the construction of all its shielding applications.  Tungsten is a radiation dense element that can be machined into functional products for use in nuclear medicine.  We can make ALMOST anything out of tungsten!   John A. Zehner, President and CEO Mr. Zehner has over 15 years of experience in the Nuclear Medicine field.  He has been part of several start-ups, mergers and acquisitions in his field.  In 1993, he assisted in launching of Northern Virginia Isotopes, Inc., a nuclear pharmacy focused on distributing radioactive pharmaceuticals for diagnosis and therapy for the Washington D.C. market.  In 1994, Mr. Zehner established a nuclear pharmacy in Winchester, Virginia called Valley Isotopes, Inc.  In 1995, he led the merger of three nuclear pharmacies to form Eastern Isotopes, Inc.  In 1998, he established the pharmaceutical manufacturing division of FDG within Eastern Isotopes, Inc. In 1999, Mr. Zehner became the President and COO of Eastern Isotopes, Inc.  Under his leadership, Mr. Zehner grew the company from a regional distribution pharmacy, serving the Washington D.C. metro area, to a national pharmaceutical manufacturing, imaging and distribution company, serving more than 26 states.  Mr. Zehner also grew sales for Eastern Isotopes, Inc., from approximately 4 million USD to over 34 million USD, during the time period from 1998 to 2003.  Throughout this time, the company also grew from 3 nuclear pharmacies and 50 employees to 14 facilities, which consisted of pharmaceutical manufacturing plants, nuclear medicine imaging clinics and nuclear pharmacies, employing over 300 employees. In 2001, Mr. Zehner facilitated the sale of Eastern Isotopes, Inc., to IBA, SA, a Belgium life science company, with an earn out period.  The exact terms of the sale remain confidential.  During this earn-out period, Mr. Zehner had advisory responsibilities for IBA S.A. affiliates in France, Italy and Belgium. Mr. Zehner regularly presented overviews, on behalf of Eastern Isotopes, Inc., to academic institutions, investors, large clients and various nuclear medicine vendors.  He also delivered an educational presentation to the Institute of Clinical PET, (currently the Academy of Molecular Imaging) on the topic of opportunities in cyclotrons.  During his tenure, Eastern Isotopes, Inc. was awarded the largest contract for FDG through a group purchasing organization (GPO) which represented over 1,500 hospitals.  Eastern Isotopes, Inc. also developed joint ventures with the University of West Virginia, the Medical College of Virginia and ADAC (recently acquired by Phillips. Mr. Zehner’s background includes extensive experience in regulatory affairs with the Nuclear Regulatory Commission (NRC), the Food and Drug Administration (FDA), the Department of Transportation (DOT) and various state pharmacy boards.  He has developed and presented budgets, financial projections and market forecasts to investors and various financial institutions on numerous occasions.  Mr. Zehner is also a qualified nuclear pharmacist, with experience in 5 different states.  He has held the position of radiation safety officer for 4 different companies, including Eastern Isotopes, Inc. and Amersham Health.  He also has had direct experience as a cyclotron operator for drug manufacturing.    

Text Box: E-mail:  sales@nukemed.com               (866)-613-7587              

Text Box: About Us Line

 

 

 

 

 

 

 

 

 

 

 

 

Text Box: © 2003, 2004, 2005, 2006, 2007, 2008    All Rights Reserved.

Text Box: John A. Zehner, President and CEO Mr. Zehner has over 15 years of experience in the Nuclear Medicine field.  He has been part of several start-ups, mergers and acquisitions in his field.  In 1993, he assisted in launching of Northern Virginia Isotopes, Inc., a nuclear pharmacy focused on distributing radioactive pharmaceuticals for diagnosis and therapy for the Washington D.C. market.  In 1994, Mr. Zehner established a nuclear pharmacy in Winchester, Virginia called Valley Isotopes, Inc.  In 1995, he led the merger of three nuclear pharmacies to form Eastern Isotopes, Inc.  In 1998, he established the pharmaceutical manufacturing division of FDG within Eastern Isotopes, Inc. In 1999, Mr. Zehner became the President and COO of Eastern Isotopes, Inc.  Under his leadership, Mr. Zehner grew the company from a regional distribution pharmacy, serving the Washington D.C. metro area, to a national pharmaceutical manufacturing, imaging and distribution company, serving more than 26 states.  Mr. Zehner also grew sales for Eastern Isotopes, Inc., from approximately 4 million USD to over 34 million USD, during the time period from 1998 to 2003.  Throughout this time, the company also grew from 3 nuclear pharmacies and 50 employees to 14 facilities, which consisted of pharmaceutical manufacturing plants, nuclear medicine imaging clinics and nuclear pharmacies, employing over 300 employees. In 2001, Mr. Zehner facilitated the sale of Eastern Isotopes, Inc., to IBA, SA, a Belgium life science company, with an earn out period.  The exact terms of the sale remain confidential.  During this earn-out period, Mr. Zehner had advisory responsibilities for IBA S.A. affiliates in France, Italy and Belgium. Mr. Zehner regularly presented overviews, on behalf of Eastern Isotopes, Inc., to academic institutions, investors, large clients and various nuclear medicine vendors.  He also delivered an educational presentation to the Institute of Clinical PET, (currently the Academy of Molecular Imaging) on the topic of opportunities in cyclotrons.  During his tenure, Eastern Isotopes, Inc. was awarded the largest contract for FDG through a group purchasing organization (GPO) which represented over 1,500 hospitals.  Eastern Isotopes, Inc. also developed joint ventures with the University of West Virginia, the Medical College of Virginia and ADAC (recently acquired by Phillips. Mr. Zehner’s background includes extensive experience in regulatory affairs with the Nuclear Regulatory Commission (NRC), the Food and Drug Administration (FDA), the Department of Transportation (DOT) and various state pharmacy boards.  He has developed and presented budgets, financial projections and market forecasts to investors and various financial institutions on numerous occasions.  Mr. Zehner is also a qualified nuclear pharmacist, with experience in 5 different states.  He has held the position of radiation safety officer for 4 different companies, including Eastern Isotopes, Inc. and Amersham Health.  He also has had direct experience as a cyclotron operator for drug manufacturing.